Self emulsifying drug delivery system
View Patent ↗The present invention claims and discloses a pharmaceutical composition suitable for oral administration, in form of an emulsion pre-concentrate, comprising (i) a compound of formula (I); (ii) one or more surfactants; (iii) optionally an oil or semi-solid fat; said composition forming an in-situ oil-in-water emulsion upon contact with aqueous media such as gastrointestinal fluids. The composition may optionally also comprise one or more short-chain alcohols. The pharmaceutical composition is useful in the treatment of pain and inflammation.
1. An emulsion pre-concentrate suitable for oral administration, consisting essentially of:
(i) a compound of the formula (I)
(ii) one or more non-ionic surfactants, wherein the ratio of compound of formula (I):surfactant is within the range of from 1:0.3-1:3; and
(iii) optionally one or more short-chain alcohols in an amount of about 6% w/w to about 8% w/w,
wherein said emulsion pre-concentrate forms an in situ oil-in-water emulsion upon contact with aqueous media.
2. The emulsion pre-concentrate according to claim 1 , wherein the amount of the compound of formula (I) is from 50-1500 mg per unit dose.
3. The emulsion pre-concentrate according to claim 2 , wherein the amount of the compound of formula (I) is 125-500 mg per unit dose.
4. The emulsion pre-concentrate according to claim 1 , wherein the non-ionic surfactant is a block co-polymer.
5. The emulsion pre-concentrate according to claim 1 , wherein the non-ionic surfactant is a poloxamer.
6. The emulsion pre-concentrate according to claim 5 , wherein the non-ionic surfactant is selected from the group consisting of Poloxamer 407; Poloxamer 401; Poloxamer 237; Poloxamer 338; Poloxamer 331; Poloxamer 231; Poloxamine 908; Poloxamine 1307; Poloxamine 1107; and polyoxyethylene polyoxybutylene block copolymer.
7. The emulsion pre-concentrate according to claim 1 , wherein the total amount of surfactant(s) is from 12.5-6000 mg.
8. The emulsion pre-concentrate according to claim 7 , wherein the total amount of surfactant(s) is from 100-500 mg.
9. The emulsion pre-concentrate according to claim 1 , wherein the short-chain alcohol is selected from the group consisting of ethanol, propyleneglycol and glycerol.
10. A unit dosage form filled with an emulsion pre-concentrate according to claim 1 .
11. A unit dosage form according to claim 10 , selected from the group consisting of capsules, drinking ampoules, dose cushion, chewable soft pill, and chewy-base lozenges.
12. A unit dosage form according to claim 11 , in the form of a capsule.
13. A unit dosage form according to claim 12 , wherein said capsule is a hard gelatine capsule.
14. A unit dosage form according to claim 12 , wherein said capsule is a soft gelatine capsule.
15. An oral solution comprising an emulsion pre-concentrate according to claim 1 dissolved in water.
16. A method for the treatment of pain comprising administering an emulsion pre-concentrate according to claim 1 , to a patient in need thereof.
17. A method for the treatment of inflammation comprising administering an emulsion pre-concentrate according to claim 1 , to a patient in need thereof.
18. An emulsion pre-concentrate suitable for oral administration consisting essentially of:
(i) a compound of the formula (I)
and
(ii) one or more non-ionic surfactants, wherein the ratio of compound of formula (I):surfactant is within the range of from 1:0.3-1:3,
wherein said emulsion pre-concentrate forms an in situ oil-in-water emulsion upon contact with aqueous media.